{
    "clinical_study": {
        "@rank": "146424", 
        "arm_group": [
            {
                "arm_group_label": "Sunitinib", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Valproic acid", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II trial studies how well sunitinib malate or valproic acid works in\n      preventing high-risk uveal (eye) melanoma from spreading to other parts of the body.\n      Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents\n      these cells from growing. Valproic acid may change the expression of some genes in uveal\n      melanoma and suppress tumor growth."
        }, 
        "brief_title": "Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma", 
        "condition": [
            "Ciliary Body and Choroid Melanoma, Medium/Large Size", 
            "Ciliary Body and Choroid Melanoma, Small Size", 
            "Iris Melanoma", 
            "Stage I Intraocular Melanoma", 
            "Stage IIA Intraocular Melanoma", 
            "Stage IIB Intraocular Melanoma", 
            "Stage IIIA Intraocular Melanoma", 
            "Stage IIIB Intraocular Melanoma", 
            "Stage IIIC Intraocular Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Uveal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      1) To assess the efficacy of adjuvant sunitinib malate or adjuvant valproic acid used for 6\n      months to improve overall survival (OS) at 2 years in patients with high-risk uveal\n      melanoma.\n\n      SECONDARY OBJECTIVES:\n\n        1. To assess the efficacy of adjuvant sunitinib malate and adjuvant valproic acid used for\n           6 months in preventing the development of distal metastases (relapse-free survival,\n           RFS) in patients with high-risk uveal melanoma.\n\n        2. To confirm the safety and tolerability of 6 months of adjuvant sunitinib and adjuvant\n           valproic acid in patients with high-risk uveal melanoma.\n\n        3. To assess the quality of life during the adjuvant treatment.\n\n      TERTIARY OBJECTIVES:\n\n      1) To determine whether blood myeloid-derived suppressor cells (MDSCs) concentration and\n      other inflammatory cytokines correlates with OS and RFS.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive sunitinib malate orally (PO) daily for 6 months in the absence of\n      disease progression or unacceptable toxicity.\n\n      ARM II: Patients receive valproic acid PO daily for 6 months in the absence of disease\n      progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 3 months for 2 years,\n      every 6 months for 3 years, and then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age >= 18 years old.\n\n          2. Histologically-confirmed primary uveal melanoma.\n\n          3. Definitive local treatment for primary tumor, including surgical resection\n             (enucleation) or radiation therapy (radioactive plaque or external proton beam).\n\n          4. High risk for distal recurrence defined as any of the following conditions: A) -\n             Confirmed both monosomy 3 and 8q amplification; B) - Class II tumor.\n\n          5. Less than 6 months from the date that local treatment (surgical or radiation) of the\n             primary tumor was finalized.\n\n          6. Karnofsky performance status (PS) scores of 70 or greater.\n\n          7. If female, no pregnancy.\n\n          8. If of child-bearing potential (< one year post-menopausal), must agree to practice an\n             effective method of avoiding pregnancy (including oral or implanted contraceptives,\n             intrauterine device, condom, diaphragm with spermicidal, cervical cap, abstinence or\n             sterile sex partner) from the time informed consent is signed (women only) or the\n             time of initiation of sunitinib (men only); both men and women must agree to continue\n             using such precautions while receiving sunitinib or valproic acid and for 30 days\n             after the final dose.\n\n          9. Adequate organ function that has been determined within 2 weeks prior to the study\n             entry, defined as:\n\n               -  Absolute neutrophil count (ANC) \u2265 1500/mm3, platelets \u2265 100,000/mm3, and\n                  hemoglobin \u2265 8 g/dl\n\n               -  Serum creatinine < 1.5 times upper limit of normal range (ULN) or creatinine\n                  clearance \u2265 40 ml/min\n\n               -  Serum bilirubin < 1.5 times ULN and serum albumin > 2.0 g/dl\n\n               -  Adequate cardiac function (EF> 50%) based on MUGA scan\n\n        Exclusion Criteria:\n\n          1. Other malignancy within 5 years, except curatively treated non-melanomatous skin\n             cancer, curatively treated carcinoma in situ of the uterine cervix, or early stage\n             (stage I or IIa) prostate cancer.\n\n          2. Metastatic uveal melanoma.\n\n          3. History of severe allergic reaction to sunitinib or valproic acid; inability to\n             receive sunitinib or valproic acid.\n\n          4. Previous treatment with sunitinib or valproic acid for uveal melanoma.\n\n          5. Active treatment with valproic acid for non-oncological conditions, if this cannot be\n             safely switched to an alternative agent.\n\n          6. Active epilepsy or convulsive conditions that require continuous use of\n             anticonvulsants.\n\n          7. Patients with known urea cycle disorders (i.e.: ornithine transcarbamylase\n             deficiency).\n\n          8. Severe cardiovascular disease within 6 months, including myocardial infarction,\n             severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic\n             congestive heart failure, cerebro-vascular accident or transient ischemic attack,\n             pulmonary embolism, life threatening arrhythmias, uncontrollable hypertension or QT\n             prolongation syndrome.\n\n          9. History of active liver disease (i.e. cirrhosis, viral or autoimmune hepatitis,\n             etc.).\n\n         10. Pregnancy or unwillingness to stop breast-feeding.\n\n         11. Prior myelosuppressive chemotherapy or other investigational drug therapy within the\n             last 6 months prior to initiation of sunitinib or valproic acid.\n\n         12. Current evidence of hematemesis, melena or gross hematuria.\n\n         13. History or presence of any significant bleeding disorders.\n\n         14. Concurrent use of a strong CYP3A4 inhibitor or inducer (refer to Section 7). These\n             medications should be discontinued or switched to a different medication with a\n             weaker CYP3A4 interaction prior to enrollment into the study. If patients need to\n             continue the same medication(s), they are excluded from the study.\n\n         15. Chronic usage of aspirin greater than 81 mg/day.\n\n         16. Unable to render informed consent and to follow protocol requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068586", 
            "org_study_id": "13P.377", 
            "secondary_id": "2013-047"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sunitinib", 
                "description": "Given PO", 
                "intervention_name": "Sunitinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sunitinib malate", 
                    "Sutent", 
                    "SU11248"
                ]
            }, 
            {
                "arm_group_label": "Valproic acid", 
                "description": "Given PO", 
                "intervention_name": "Valproic Acid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "VPA", 
                    "Valproate", 
                    "Valproate sodium", 
                    "Depakote", 
                    "Epilim", 
                    "Valparin", 
                    "Valpro", 
                    "Stavzor"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valproic Acid", 
                "Sunitinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 24, 2014", 
        "link": [
            {
                "description": "Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center", 
                "url": "http://www.KimmelCancerCenter.org"
            }, 
            {
                "description": "Thomas Jefferson University Hospitals", 
                "url": "http://www.JeffersonHospital.org"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Takami Sato, MD"
            }, 
            "contact_backup": {
                "email": "MaryAnn.Laudadio@jefferson.edu", 
                "last_name": "Mary Ann Laudadio, RN", 
                "phone": "215-955-9980"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19107"
                }, 
                "name": "Thomas Jefferson University"
            }, 
            "investigator": [
                {
                    "last_name": "Jianqing Lin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kendra Feeney, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Mastrangelo, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Carol Shields, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jerry Shields, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma", 
        "overall_contact": {
            "last_name": "Takami Sato, MD", 
            "phone": "215-955-8874"
        }, 
        "overall_contact_backup": {
            "email": "MaryAnn.Laudadio@jefferson.edu", 
            "last_name": "Mary Ann Laudadio, RN", 
            "phone": "215-955-9980"
        }, 
        "overall_official": {
            "affiliation": "Thomas Jefferson University", 
            "last_name": "Takami Sato, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "Time of definitive treatment of the primary tumor until death from any cause, assessed at 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068586"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Relapse-free survival", 
                "safety_issue": "No", 
                "time_frame": "Time of definitive treatment of the primary tumor until confirmed metastatic relapse or death from any cause, assessed at 2 years"
            }, 
            {
                "description": "Defined as the proportion of patients able to complete 6 months of treatment, including those who underwent dose reduction", 
                "measure": "Tolerability", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Thomas Jefferson University", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Thomas Jefferson University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}